Key Highlights
• Creative Medical Technology Holdings (NASDAQ: CELZ) raised approximately $4.5 million by adjusting warrant terms with existing holders.
• The company lowered the exercise price of 2,790,340 existing warrants from $2.86 to $1.60 per share.
• Holders received new warrants for 5,580,680 shares at the same $1.60 exercise price.
• Proceeds will fund working capital and general corporate needs.
Financing Deal Announced
Creative Medical Technology Holdings (NASDAQ: CELZ) has restructured its warrant agreements, generating fresh capital to support its operations in the regenerative medicine sector. The company reached agreements with warrant holders to exercise existing options under revised terms, providing an immediate influx of funds.
Warrant Terms Adjusted
The exercise price of 2,790,340 existing warrants was reduced from $2.86 to $1.60 per share. This adjustment led to the exercise of these warrants, resulting in gross proceeds of approximately $4.5 million for the company. Such modifications are common in biotech financing, where companies seek to improve liquidity while encouraging early conversion of outstanding warrants.
New Warrants Issued
As part of the transaction, holders were granted new warrants to purchase an aggregate of 5,580,680 shares at the same $1.60 exercise price. These new warrants will not be exercisable until the company secures shareholder approval, after which they will remain valid for five years. This approach allows the company to secure near-term funding while preserving future equity opportunities.
Capital Allocation Plans
The proceeds from the warrant exercise will be used for working capital and general corporate purposes. While specific allocation details were not provided, the funding is expected to enhance the company’s operational flexibility. For small-cap biotech firms, such capital infusions are often critical for sustaining research and development initiatives.
Registration and Compliance
333-291713), which became effective in December 2025. The company has also committed to filing a resale registration statement for the new warrants within 30 days. Until registered, these securities remain subject to federal and state restrictions on tradability.
Advisory Fees and Costs
Roth Capital Partners acted as the financial advisor for the transaction, receiving a fee equal to 8% of the gross proceeds. Additionally, the firm was reimbursed $50,000 for legal expenses. Such arrangements are typical in warrant restructurings, where investment banks play a key role in negotiating terms and ensuring compliance.
Executive Compensation Update
On July 1, 2026, the company’s compensation committee approved a bonus for its Chief Executive Officer in the amount of $100,000. The decision reflects ongoing efforts to align leadership incentives with corporate objectives. Further details regarding performance criteria were not disclosed in the filing.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...